A
Anita Sarkar
Researcher at Scripps Research Institute
Publications - 32
Citations - 1688
Anita Sarkar is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Glycan & HIV vaccine. The author has an hindex of 18, co-authored 29 publications receiving 1348 citations. Previous affiliations of Anita Sarkar include University of Grenoble & Indian Institutes of Technology.
Papers
More filters
Journal ArticleDOI
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
Joseph G. Jardine,Daniel W. Kulp,Colin Havenar-Daughton,Anita Sarkar,Bryan Briney,Devin Sok,Fabian Sesterhenn,June Ereño-Orbea,Oleksandr Kalyuzhniy,Isaiah Deresa,Isaiah Deresa,Xiaozhen Hu,Skye Spencer,Meaghan Jones,Erik Georgeson,Yumiko Adachi,Michael Kubitz,Allan C. deCamp,Jean-Philippe Julien,Ian A. Wilson,Dennis R. Burton,Shane Crotty,Shane Crotty,Shane Crotty,William R. Schief +24 more
TL;DR: An immunogen that could engage B cells from HIV-uninfected individuals that express the germline versions of the immunoglobulin genes harbored by a particular class of bNAbs is engineered, suggesting that the immunogen is a promising candidate for a human vaccine prime.
Journal ArticleDOI
Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
Bryan Briney,Devin Sok,Joseph G. Jardine,Daniel W. Kulp,Patrick Skog,Sergey Menis,Ron Jacak,Oleksandr Kalyuzhniy,Natalia de Val,Fabian Sesterhenn,Khoa Le,Alejandra Ramos,Meaghan Jones,Karen L. Saye-Francisco,Tanya R. Blane,Skye Spencer,Erik Georgeson,Xiaozhen Hu,Gabriel Ozorowski,Yumiko Adachi,Michael Kubitz,Anita Sarkar,Ian A. Wilson,Andrew B. Ward,David Nemazee,Dennis R. Burton,William R. Schief +26 more
TL;DR: Functional and genetic characteristics indicate that the boosted mAbs are consistent with partially mature VRC01-class antibodies and place them on a maturation trajectory that leads toward matureVRC 01-class bnAbs, and the results show how reductionist sequential immunization can guide maturation of HIV bnAb responses.
Journal ArticleDOI
A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans
Devin Sok,Matthias Pauthner,Bryan Briney,Jeong Hyun Lee,Karen L. Saye-Francisco,Jessica Hsueh,Alejandra Ramos,Khoa Le,Meaghan Jones,Joseph G. Jardine,Raiza Bastidas,Anita Sarkar,Chi-Hui Liang,Sachin S. Shivatare,Chung-Yi Wu,William R. Schief,Chi-Huey Wong,Ian A. Wilson,Andrew B. Ward,Jiang Zhu,Pascal Poignard,Dennis R. Burton +21 more
TL;DR: The isolation of new bnAbs targeting the (324)GDIR(327) peptide stretch at the base of the gp120 V3 loop and its nearby glycans is described, finding that this peptide Stretch constitutes part of the CCR5 co-receptor binding site, with the high-mannose patch glycans serving to camouflage it from most antibodies.
Journal ArticleDOI
The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.
Colin Havenar-Daughton,Colin Havenar-Daughton,Anita Sarkar,Anita Sarkar,Daniel W. Kulp,Laura Toy,Laura Toy,Xiaozhen Hu,Xiaozhen Hu,Isaiah Deresa,Oleksandr Kalyuzhniy,Oleksandr Kalyuzhniy,Kirti Kaushik,Kirti Kaushik,Amit A. Upadhyay,Sergey Menis,Sergey Menis,Elise Landais,Elise Landais,Liwei Cao,Jolene K. Diedrich,Sonu Kumar,Sonu Kumar,Torben Schiffner,Torben Schiffner,Samantha M. Reiss,Samantha M. Reiss,Grégory Seumois,John R. Yates,James C. Paulson,Steven E. Bosinger,Ian A. Wilson,William R. Schief,Shane Crotty,Shane Crotty,Shane Crotty +35 more
TL;DR: Assessment of antigen-specific human naive B cells among hundreds of millions of B cells from multiple donors may be used as pre–phase 1 ex vivo human testing to potentially forecast B cell and Ab responses to new vaccine designs.
Journal ArticleDOI
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design
Joseph G. Jardine,Devin Sok,Jean-Philippe Julien,Bryan Briney,Anita Sarkar,Chi Hui Liang,Erin A. Scherer,Carole J. Henry Dunand,Yumiko Adachi,Devan Diwanji,Jessica Hsueh,Meaghan Jones,Meaghan Jones,Oleksandr Kalyuzhniy,Michael Kubitz,Skye Spencer,Matthias Pauthner,Karen L. Saye-Francisco,Fabian Sesterhenn,Patrick C. Wilson,Denise M. Galloway,Robyn L. Stanfield,Ian A. Wilson,Dennis R. Burton,William R. Schief +24 more
TL;DR: A reductionist approach to vaccine design, guided by antibody and antigen structure, could be applied to design candidate vaccines for other HIV bnAbs or protective Abs against other pathogens.